参考文献/References:
[1] 葛坚,王宁利,黎晓新,姚克,孙兴怀.眼科学[M].北京:人民卫生出版社,2015:287.
GE J,WANG NL,LI XX,YAO K,SUN XH.Ophthalmology[M].Beijing:People’s Medical Publishing House,2015:287.
[2] TRIPATHI RC,LI J,TRIPATHI BJ,CHALAM KV,ADAMIS AP.Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma[J].Ophthalmology,1998,105(2):232-237.
[3] VASDUV D,BLAIR MP,GALASSO J,KAPUR R,VAJARANANT AT.Intravitreal bevacizumab for neovascular glaucoma[J].J Ocul Pharmaeol Ther,2009,25(5):453-458.
[4] 吴敏,薛黎萍,和丹,胡竹林,肖丽波.23G玻璃体切割术联合全视网膜光凝和二期Ahmed引流阀植入治疗新生血管性青光眼疗效探讨[J].中国实用眼科杂志,2015,33(11):1284-1287.
WU M,XUE LP,HE D,HU ZL,XIAO LB.The outcome of 23 Gauge vitrectomy combined with pan retina photocoagulation followed by Ahmed glaucoma valve implantation in neovascular glaucoma[J].Chin J Pract Ophthalmol,2015,33(11):1284-1287.
[5] 中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南(2014年)[J].中华眼科杂志,2014,50(11):851-865.
FUNDUS DISEASES GROUP OF OPHTHALMOLOGY SOCIETY OF CHINESE MEDICAL ASSOCIATION.Guidelines for clinical diagnosis and treatment of diabetic retinopathy in China (2014)[J].Chin J Ophthalmol,2014,50 (11):851-865.
[6] 李凤鸣,谢立信.中华眼科学[M].北京:人民卫生出版社,2014:1888-1889.
LI FM,XIE LX.Chinese ophthalmology[M].Beijing:People’s Medical Publishing House,2014:1888-1889.
[7] CLUGRU D,CLUGRU M.Neovascular glaucoma--etipa-thogeny and diagnosis[J].Oftalmologia,2012,56(2):3-14.
[8] HOU XR,MIAO H,TAO Y,LI XX,WONG IY.Expression of cytokines on the iris of patients with neovascular glaucoma[J].Acta Ophthalmol,2014,93(2):100-104.
[9] CHALAM KV,BRAR VS,MURTHY RK.Human ciliary epithelium as a source of synthesis and secretion of vascular endothelial growth factor in neovascular glaucoma[J].Ophthalmology,2014,132(11):1350-1354.
[10] NOMA H,MIMURA T,YASUDA K,SHIMURA M.Vascular endothelial growth factor and its soluble receptors-1 and -2 in iris neovascularization and neovascular glaucoma[J].Ophthalmologica,2014,232(2):102-109.
[11] WANG D,CHOI KS,LEE SJ.Serum concentration of vascular endothelial growth factor after bilateral intravitreal injection of bevacizumab[J].Korean J Ophthalmol,2014,28(1):32-38.
[12] MATSUYAMA K,OGATA N,MATSUOKA M,WADA M,TAKAHASHI K,NISHIMURA T.Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab[J].Br J Ophthalmol,2010,94(9):1215-1218.
[13] 师留坤,杨瑾.抗VEGF药物辅助治疗新生血管性青光眼[J].国际眼科纵览,2015,39(6):376-381.
SHI LK,YANG J.Adjuvant treatment of neovascular glaucoma with anti-VEGF[J].Int Rev Ophthalmol,2015,39(6):376-381.
[14] 刘红,秦平.玻璃体腔内注射Avastin联合睫状体光凝治疗新生血管性青光眼[J].新乡医学院学报,2013,30(3):216-217,220.
LIU H,QIN P.Intravitreal injection of Avastin combined with cyclophotocoagulation for neovascular glaucoma[J].J Xinxiang Med Coll,2013,30(3):216-217,220.
[15] BROWN DM,NGUYEN QD,MARCUS DM,BOYER DS,PATEL S,FEINER L,et al.Long-term outcomes of ranibizumab therapy for diabetic macular edema:the 36-month results from two phase III trials:RISE and RIDE[J].Ophthalmology,2013,120(10):2013-2022.
[16] SUN Y,YONG L,PENG Z,HUI JW,XIAN RH,ZE QR,et al.Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term[J].BMC Ophthalmol,2016,16(1):150.
相似文献/References:
[1]杜玮 刘子扬 周艳艳 雒雷鸣.糖尿病视网膜病变与血清胆红素水平的关系[J].眼科新进展,2012,32(5):000.
[2]赵宁 万超 刘宁宁 王建英 陈蕾 才娜.玻璃体切割联合超全视网膜光凝、白内障摘出术治疗新生血管性青光眼[J].眼科新进展,2012,32(6):000.
[3]代应辉 李娟 王剑锋 秦梅 高自清.前部视网膜、睫状体冷凝联合复合式小梁切除术治疗新生血管性青光眼的临床研究[J].眼科新进展,2012,32(6):000.
[4]范松涛 卢建民.阿司匹林与糖尿病患者玻璃体出血以及玻璃体切割术疗效的相关性研究[J].眼科新进展,2012,32(11):000.
[5]李秀云 李聪伶 王俊 李娜 赵岩松.Avastin联合周边视网膜冷冻术治疗晚期新生血管性青光眼[J].眼科新进展,2012,32(12):000.
[6]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[7]李朝晖 崔治华 胡晓英 孟丽珠 张敬维.糖尿病视网膜病变激光面积与疗效的分析[J].眼科新进展,2013,33(2):000.
[8]冯冬梅 朱鸿 施彩虹.CXC趋化因子及其受体在糖尿病视网膜病变中的作用[J].眼科新进展,2013,33(6):000.
[9]牛淑玲.糖尿病视网膜病变患者HbAlc、FPG与血小板参数的变化及危险因素分析[J].眼科新进展,2013,33(7):000.
[10]张启珍 罗顺利 王勤.改良小梁切除术联合睫状体视网膜冷凝治疗新生血管性青光眼[J].眼科新进展,2013,33(7):000.